Microbiological Profile of VAP Patients in Respiratory ICU (VAP)

February 13, 2023 updated by: Manar Abdelhameed Hassan Ali, Assiut University

Microbiological Profile of Ventilator Associated Pneumonia in Respiratory Intensive Care Unit of Assiut University Hospital

Identification of the microbial profile of Ventilator associated pneumonia causing microorganisms among Respiratory ICU patients .

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Ventilator-associated pneumonia (VAP) is one of the common serious infectious diseases encountered in the intensive care unit (ICU), which highly affects the healthcare cost and patient prognosis.

All-cause of mortality associated with VAP has been reported to range from 20% to 50%.

The etiology of VAP and their antimicrobial susceptibility pattern varies with different patient populations and types of ICUs.

VAP may be caused by a wide spectrum of bacterial pathogens, which may be polymicrobial and are rarely due to viral or fungal pathogens in immune-competent hosts.

Common etiologic agents are Gram-negative bacilli such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter spp. and Staphylococcus aureus among Gram-positive cocci.

Due to the increased incidence of MDR organisms in Intensive Care Units (ICUs), early and correct diagnosis of VAP is mandatory for optimal antibiotic therapy. The frequency of specific MDR pathogens causing VAP varies in hospitals, patient populations. Also varies according underlying disease.

this study will be conducted in respiratory intensive care unit, chest disease and tuberculosis department at Assiut university hospitals.

Study Type

Observational

Enrollment (Anticipated)

86

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Age more than 18 years.

Mechanically ventilated patient who developed pneumonia after48 hours after endotracheal intubation.

Description

Inclusion Criteria:

  1. Mechanically ventilated patient who developed pneumonia after48 hours after endotracheal intubation.
  2. Age > 18 years.

Exclusion Criteria:

  1. Patients with clinical and radiological signs suggestive of pneumonia before intubation (community acquired pneumonia or hospital acquired pneumonia)
  2. Patients age ≤18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microbiological profile of ventilator associated pneumonia in Respiratory ICU in Assiut University Hospital.
Time Frame: 1 year
Identify the microbial profile of VAP causing microorganisms among ICU patients, antimicrobial susceptibility patterns among the frequently isolated organisms and resistant strains.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Director: mohammed M Abdelhadi, PhD, Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 1, 2023

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

February 1, 2024

Study Registration Dates

First Submitted

February 13, 2023

First Submitted That Met QC Criteria

February 13, 2023

First Posted (Estimate)

February 22, 2023

Study Record Updates

Last Update Posted (Estimate)

February 22, 2023

Last Update Submitted That Met QC Criteria

February 13, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Microbiological profile of VAP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on VAP - Ventilator Associated Pneumonia

Clinical Trials on blood and sputum culture

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe